Q3 EPS Forecast for USANA Health Sciences Boosted by Analyst

Posted by Brenda Bartman on Aug 11th, 2026

USANA Health Sciences, Inc. (NYSE:USNA – Free Report) – Investment analysts at Sidoti raised their Q3 2026 earnings per share (EPS) estimates for shares of USANA Health Sciences in a research note issued to investors on Thursday, August 6th. Sidoti analyst A. Lebiedzinski now expects that the company will post earnings per share of $0.11 for the quarter, up from their prior estimate of $0.09. The consensus estimate for USANA Health Sciences’ current full-year earnings is $0.76 per share. Sidoti also issued estimates for USANA Health Sciences’ Q1 2027 earnings at $0.34 EPS and Q2 2027 earnings at $0.46 EPS.

USANA Health Sciences (NYSE:USNA – Get Free Report) last issued its quarterly earnings data on Tuesday, August 4th. The company reported ($0.07) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.43 by ($0.50). The company had revenue of $223.27 million during the quarter, compared to analysts’ expectations of $235.00 million. USANA Health Sciences had a negative net margin of 2.43% and a positive return on equity of 3.41%. USANA Health Sciences has set its FY 2026 guidance at 0.760-0.760 EPS.

A number of other research analysts have also recently commented on the company. Wall Street Zen cut USANA Health Sciences from a “buy” rating to a “hold” rating in a research note on Saturday. Zacks Research cut USANA Health Sciences from a “hold” rating to a “strong sell” rating in a research note on Thursday, August 6th. Finally, Weiss Ratings reiterated a “sell (d)” rating on shares of USANA Health Sciences in a report on Wednesday, June 24th. Two research analysts have rated the stock with a Sell rating, Based on data from MarketBeat, USANA Health Sciences presently has a consensus rating of “Sell”.

Read Our Latest Stock Analysis on USNA

USANA Health Sciences Stock Performance

USANA Health Sciences stock opened at $14.31 on Monday. USANA Health Sciences has a fifty-two week low of $14.19 and a fifty-two week high of $32.32. The firm has a 50 day moving average price of $20.33 and a 200 day moving average price of $19.59. The company has a market capitalization of $264.16 million, a PE ratio of -11.83, a price-to-earnings-growth ratio of 1.70 and a beta of 0.73.

Institutional Trading of USANA Health Sciences

A number of large investors have recently made changes to their positions in the company. Versant Capital Management Inc lifted its stake in USANA Health Sciences by 1,472.3% in the second quarter. Versant Capital Management Inc now owns 1,588 shares of the company’s stock worth $34,000 after acquiring an additional 1,487 shares during the last quarter. National Bank of Canada FI grew its holdings in USANA Health Sciences by 166.6% during the 3rd quarter. National Bank of Canada FI now owns 1,922 shares of the company’s stock worth $53,000 after acquiring an additional 1,201 shares in the last quarter. State of Wyoming purchased a new stake in shares of USANA Health Sciences in the 1st quarter valued at approximately $57,000. Tower Research Capital LLC TRC increased its position in shares of USANA Health Sciences by 382.5% in the 2nd quarter. Tower Research Capital LLC TRC now owns 2,398 shares of the company’s stock valued at $73,000 after purchasing an additional 1,901 shares during the last quarter. Finally, Parallel Advisors LLC raised its holdings in shares of USANA Health Sciences by 1,354.3% in the 4th quarter. Parallel Advisors LLC now owns 3,854 shares of the company’s stock valued at $76,000 after purchasing an additional 3,589 shares in the last quarter. 54.25% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at USANA Health Sciences

In related news, Director John Turman Fleming sold 2,450 shares of the business’s stock in a transaction on Monday, June 1st. The stock was sold at an average price of $17.93, for a total transaction of $43,928.50. Following the completion of the transaction, the director directly owned 4,230 shares of the company’s stock, valued at $75,843.90. The trade was a 36.68% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CFO G Doug Iiekking sold 5,360 shares of the company’s stock in a transaction dated Wednesday, May 27th. The stock was sold at an average price of $18.75, for a total value of $100,500.00. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders sold 13,869 shares of company stock worth $261,441. Company insiders own 0.82% of the company’s stock.

USANA Health Sciences Company Profile

(Get Free Report)

USANA Health Sciences, Inc is a Utah‐based company that develops, manufactures and distributes nutritional supplements and personal care products through a network of independent distributors. Founded in 1992 by Dr. Myron Wentz, the company’s portfolio includes vitamins, minerals, dietary supplements, weight‐management products and skin‐care formulations. USANA’s products are formulated in its own laboratories to meet pharmaceutical‐grade standards, and the company has invested heavily in research and development and quality control to support its offerings.

Operating primarily through a direct selling model, USANA serves markets in North America, Asia Pacific, Europe and Latin America.